Recombinant DNA Technology Market Growth, Demand and Challenges of the Key Industry Players 2023-28

1
Global Recombinant DNA Technology Market Research
and Forecast Report 2023-2028

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Recombinant DNA Technology Market Global
  Industry Trends, Share, Size, Growth, Opportunity
  and Forecast 2023-2028," the global recombinant
  DNA technology market size reached US 729.8
  Billion in 2022.
• Recombinant deoxyribonucleic acid (DNA)
  technology refers to the process of altering
  genetic materials to obtain desired
  characteristics in living organisms or their
  products. It involves multiple steps, such as
  isolation of genetic material, restriction enzyme
  digestion, amplification using polymerase chain
  reaction (PCR), ligation of DNA molecules, and
  insertion of recombinant DNA into the host.
• It is widely used in manufacturing
  pharmaceuticals, novel enzymes for food
  processing, production of genetically modified
  organisms (GMO), gene therapy, and clinical
  diagnosis. Recombinant DNA technology is vital in
  improving health, enhancing food resources, and
  solving environmental problems. It also aids in
  the production of vaccines and protein therapies
  such as human insulin, interferon, and human
  growth hormone.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/recombinant-dna-technol
  ogy-market/requestsample

4
Report Description

• Global Recombinant DNA Technology Market Trends
• The global recombinant DNA technology market is
  primarily being driven by its increasing
  utilization in the pharmaceutical industry.
  Recombinant DNA technology is extensively used in
  developing vaccines and manufacturing insulin,
  human growth hormones, antibiotics, and
  monoclonal antibodies. In addition, the
  widespread adoption of gene therapy in the
  healthcare industry to treat cancer,
  cardiovascular diseases (CVDs), infertility, and
  genetic diseases is acting as another
  growth-inducing factor. Furthermore, the
  increasing demand for recombinant DNA technology
  in the agriculture industry to develop GMO crops
  with better yield, microbial resistance, drought
  resistance, salt tolerance, and high nutrition
  levels is providing an impetus to the market
  growth. Additionally, the introduction of new
  technologies, such as Clustered regularly
  interspaced short palindromic repeats (CRISPR or
  Cas9), Zinc-finger nucleases (ZFNs), and
  transcription activator-like effector nucleases
  (TALENs) for simple, cost-effective, and precise
  genome editing is creating a positive outlook for
  the market. Other factors, including increasing
  demand for recombinant DNA technology for
  improving different health conditions, extensive
  research and development (RD) activities in
  novel therapeutics, and widespread utilization in
  the production of transgenic animals, are
  anticipated to drive the market growth.
• Looking forward, the market is expected to reach
  US 966.8 Billion by 2028, exhibiting a CAGR of
  4.7 during 2023-2028.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/recombinant-dna-technol
  ogy-market

5
Report Segmentation

• Breakup by Product
• Medical
• Therapeutic Agent
• Human Protein
• Vaccines
• Non-Medical
• Biotech Crops
• Specialty Chemicals
• Others
•  
• Breakup by Component
• Expression System
• Cloning Vector
• Breakup by Application
• Food and Agriculture

6
Report Segmentation

• Health and Disease
• Environment
• Others
• Breakup by End User
• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Others
• Breakup by Region
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7
Competitive Landscape with Key Players

• Amgen Inc
• Cibus
• F.Hoffmann-La Roche Ltd
• GenScript
• GlaxoSmithKline plc.
• Horizon Discovery Group plc
• Merck KGaA
• New England Biolabs
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi S.A
• Syngene International Ltd (Biocon Limited).

8
Key Questions Answered in the Report
9
Key Questions Answered in the Report
10
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Recombinant DNA
  Technology Market    5.1    Market Overview   
  5.2    Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by Product    6.1  
   Medical        6.1.1 Market Trends       
  6.1.2 Key Segments           6.1.2.1 Therapeutic
  Agent           6.1.2.2 Human Protein         
   6.1.2.3 Vaccines        6.1.3 Market Forecast 
    6.2    Non-Medical        6.2.1 Market
  Trends        6.2.2 Key Segments       

11
Table of Contents

•            6.2.2.1 Biotech Crops         
   6.2.2.2 Specialty Chemicals           6.2.2.3
  Others        6.2.3 Market Forecast7   Market
  Breakup by Component    7.1    Expression
  System        7.1.1 Market Trends        7.1.2
  Market Forecast    7.2    Cloning Vector       
  7.2.1 Market Trends        7.2.2 Market
  Forecast8   Market Breakup by Application   
  8.1    Food and Agriculture        8.1.1 Market
  Trends        8.1.2 Market Forecast    8.2  
   Health and Disease        8.2.1 Market Trends 
        8.2.2 Market Forecast    8.3  
   Environment        8.3.1 Market Trends       
  8.3.2 Market Forecast    8.4    Others       
  8.4.1 Market Trends        8.4.2 Market Forecast
• 9   Market Breakup by End User    9.1  
   Biotechnology and Pharmaceutical Companies     
    9.1.1 Market Trends        9.1.2 Market
  Forecast
• For more information, visit https//www.imarcgrou
  p.com/recombinant-dna-technology-market/toc

12
Disclaimer

• 2023 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

13
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE [phone] E-MAIL
sales_at_imarcgroup.com